De novo maintenance therapy with denileukin diftitox (Ontak®) in a patient with peripheral T-cell lymphoma is associated with prolonged remission

High-dose therapy and autologous periphe

High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients

✍ Massimo Martino; Giuseppe Console; Giuseppe Irrera; Giulia Praticò; Caterina Ste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 2 views

## Abstract The recent development of reduced intensity conditioning and allotransplantation (RICT) has opened a new way to assure engraftment of donor cells while reducing early transplant‐related mortality. We evaluated the combination of high‐dose therapy and autologous peripheral blood stem cel